

Adolfo A Ferrando

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5369200/publications.pdf>

Version: 2024-02-01

124
papers

12,148
citations

66234

42
h-index

30848

102
g-index

124
all docs

124
docs citations

124
times ranked

16397
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. <i>Leukemia</i> , 2022, 36, 583-587.	3.3	5
2	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by <i>NSD2</i> Mutation in Pediatric Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2022, 12, 186-203.	7.7	17
3	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. <i>Blood</i> , 2022, 139, 399-412.	0.6	10
4	Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2022, 12, 856-871.	7.7	13
5	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. <i>Blood</i> , 2022, , .	0.6	7
6	Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 1002-1021.	7.7	22
7	Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. <i>Nature Communications</i> , 2022, 13, 1048.	5.8	12
8	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T-cell lymphoma. <i>Cell Reports</i> , 2022, 39, 110695.	2.9	13
9	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2022, 13, 2801.	5.8	25
10	FYN-TRAF3IP2 induces NF- κ B signaling-driven peripheral T-cell lymphoma. <i>Nature Cancer</i> , 2021, 2, 98-113.	5.7	19
11	Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. <i>Trends in Immunology</i> , 2021, 42, 418-431.	2.9	4
12	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. <i>Leukemia</i> , 2021, 35, 3394-3405.	3.3	28
13	Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2908-2920.e7.	0.3	12
14	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2846-2867.	7.7	83
15	The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035246.	2.9	23
16	Combinatorial ETS1-Dependent Control of Oncogenic NOTCH1 Enhancers in T-cell Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 178-197.	2.6	11
17	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	5.7	32
18	Covalent inhibition of NSD1 histone methyltransferase. <i>Nature Chemical Biology</i> , 2020, 16, 1403-1410.	3.9	52

#	ARTICLE	IF	CITATIONS
19	Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. <i>Cell Reports</i> , 2020, 30, 3280-3295.e6.	2.9	7
20	Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2020, 135, 921-933.	0.6	17
21	Expression of Vav1-Myo1F Fusion Affects T-Cell Differentiation and Induces T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 4-4.	0.6	0
22	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. <i>Blood</i> , 2020, 136, 18-20.	0.6	2
23	Mechanisms of Therapeutic Response to Tipifarnib in a Mouse Model of Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-9.	0.6	0
24	The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL. <i>Blood</i> , 2020, 136, 20-20.	0.6	1
25	Metabolic dependencies and vulnerabilities in leukemia. <i>Genes and Development</i> , 2019, 33, 1460-1474.	2.7	63
26	GATA3-Controlled Nucleosome Eviction Drives <i>MYC</i> Enhancer Activity in T-cell Development and Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1774-1791.	7.7	27
27	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. <i>Nature Medicine</i> , 2019, 25, 1938-1947.	15.2	348
28	Current perspectives in T-ALL. <i>HemaSphere</i> , 2019, 3, 181-183.	1.2	0
29	<i>Phf6</i> Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. <i>Cancer Discovery</i> , 2019, 9, 436-451.	7.7	67
30	Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models. <i>Blood</i> , 2019, 134, 3870-3870.	0.6	5
31	Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism. <i>Blood</i> , 2019, 134, 806-806.	0.6	1
32	The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. <i>Leukemia</i> , 2018, 32, 1984-1993.	3.3	26
33	RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. <i>Cancer Cell</i> , 2018, 33, 259-273.e7.	7.7	154
34	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 2018, 553, 511-514.	18.7	90
35	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 197-216.	4.2	30
36	Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. <i>Cancer Cell</i> , 2018, 34, 869-871.	7.7	10

#	ARTICLE	IF	CITATIONS
37	Can one target T-cell ALL?. Best Practice and Research in Clinical Haematology, 2018, 31, 361-366.	0.7	37
38	Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1157-1166.	15.2	63
39	Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell, 2018, 34, 136-147.e6.	7.7	39
40	Mitochondrial Complex I Inhibitor IACS-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition. Blood, 2018, 132, 4020-4020.	0.6	7
41	Suppression of GATA3 Binding Drives Selective Abrogation of NOTCH1-MYC Enhancer Activity By Nucleosome Invasion in Thymocyte Development and Leukemia. Blood, 2018, 132, 545-545.	0.6	0
42	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 764-769.	3.3	100
43	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	13.5	213
44	The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 1124-1133.	0.6	174
45	Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2006-2011.	3.3	50
46	Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2911-E2919.	3.3	108
47	Clonal evolution in leukemia. Nature Medicine, 2017, 23, 1135-1145.	15.2	93
48	Targeted cellular immunotherapy for T cell malignancies. Nature Medicine, 2017, 23, 1402-1403.	15.2	7
49	Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation, 2017, 127, 4297-4313.	3.9	89
50	A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663.	0.8	10
51	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	3.3	151
52	The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nature Reviews Cancer, 2016, 16, 494-507.	12.8	348
53	Tumor Suppressor HIPK2 Regulates Malignant Growth via Phosphorylation of Notch1. Cancer Research, 2016, 76, 4728-4740.	0.4	16
54	MMP-25 Metalloprotease Regulates Innate Immune Response through NF- κ B Signaling. Journal of Immunology, 2016, 197, 296-302.	0.4	34

#	ARTICLE	IF	CITATIONS
55	Targeting NOTCH1 in T-ALL: Starving the dragon. <i>Cell Cycle</i> , 2016, 15, 483-484.	1.3	5
56	Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. <i>Blood</i> , 2016, 128, 889-889.	0.6	0
57	Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. <i>Blood</i> , 2015, 126, 2479-2483.	0.6	36
58	Therapeutic targeting of HES1 transcriptional programs in T-ALL. <i>Blood</i> , 2015, 125, 2806-2814.	0.6	40
59	CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. <i>Cancer Cell</i> , 2015, 27, 755-768.	7.7	216
60	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7773-7778.	3.3	18
61	Aberrant Cytokine Production by Nonmalignant Cells in the Pathogenesis of Myeloproliferative Tumors and Response to JAK Inhibitor Therapies. <i>Cancer Discovery</i> , 2015, 5, 234-236.	7.7	5
62	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	13.7	749
63	How I treat T-cell acute lymphoblastic leukemia in adults. <i>Blood</i> , 2015, 126, 833-841.	0.6	179
64	Negative feedback—defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. <i>Nature Medicine</i> , 2015, 21, 563-571.	15.2	141
65	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2015, 21, 1182-1189.	15.2	180
66	The mutational landscape of cutaneous T cell lymphoma and SÅžary syndrome. <i>Nature Genetics</i> , 2015, 47, 1465-1470.	9.4	322
67	De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL. <i>Blood</i> , 2015, 126, 2627-2627.	0.6	2
68	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2014, 9, 1841-1855.	2.9	237
69	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. <i>Nature Genetics</i> , 2014, 46, 166-170.	9.4	534
70	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. <i>Nature</i> , 2014, 514, 513-517.	13.7	340
71	Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL). <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 754-759.	1.3	14
72	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2014, 20, 1130-1137.	15.2	349

#	ARTICLE	IF	CITATIONS
73	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2013, 24, 766-776.	7.7	220
74	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. <i>Nature Medicine</i> , 2013, 19, 368-371.	15.2	304
75	The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. <i>Cell</i> , 2013, 153, 1552-1566.	13.5	277
76	SOX11 is a mantle cell lymphoma oncogene. <i>Blood</i> , 2013, 121, 2169-2170.	0.6	16
77	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 811-811.	0.6	3
78	Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 846-846.	0.6	1
79	Therapeutic Effect of $\hat{3}$ -Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK. <i>Cancer Cell</i> , 2012, 22, 222-234.	7.7	108
80	Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. <i>Nature Medicine</i> , 2012, 18, 436-440.	15.2	138
81	Therapeutic Utility of PI3K $\hat{3}$ Inhibition in Leukemogenesis and Tumor Cell Survival. <i>Blood</i> , 2012, 120, 1492-1492.	0.6	1
82	Familial and Acquired SH2B3 mutations in ALL. <i>Blood</i> , 2012, 120, 1326-1326.	0.6	0
83	Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 294-294.	0.6	0
84	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. <i>Blood</i> , 2012, 120, 285-285.	0.6	5
85	Using the Zebrafish As a Tool for Modeling Systemic Mastocytosis,. <i>Blood</i> , 2011, 118, 3208-3208.	0.6	0
86	ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL. <i>Blood</i> , 2011, 118, 406-406.	0.6	1
87	PHF6 mutations in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2010, 42, 338-342.	9.4	282
88	Oncogenic AKT Signaling Negatively Regulates Glucocorticoid Receptor Function to Promote Glucocorticoid Resistance In T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 11-11.	0.6	8
89	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. <i>Blood</i> , 2010, 116, 851-851.	0.6	4
90	Notch Signaling Is Required for Mast Cell Development In the Zebrafish and May Represent a Novel Therapeutic Strategy In Systemic Mastocytosis. <i>Blood</i> , 2010, 116, 930-930.	0.6	0

#	ARTICLE	IF	CITATIONS
91	MEF2C as Novel Oncogene for Early T-Cell Precursor (ETP) Leukemia. Blood, 2010, 116, 9-9.	0.6	5
92	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	0.6	0
93	Identification of a Novel T-ALL Entity with NKX2-1/NKX2-2 Rearrangements. Blood, 2010, 116, 3139-3139.	0.6	0
94	Identification of NOTCH1-Controlled Transcriptional Programs In Human T-Cell Development. Blood, 2010, 116, 2495-2495.	0.6	0
95	The role of NOTCH1 signaling in T-ALL. Hematology American Society of Hematology Education Program, 2009, 2009, 353-361.	0.9	167
96	Therapeutic Targeting of NOTCH1 Signaling in T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S205-S210.	1.4	64
97	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	0.6	111
98	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. Blood, 2009, 114, 142-142.	0.6	8
99	Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.. Blood, 2009, 114, 366-366.	0.6	8
100	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141.	0.6	0
101	Redundancy and Specificity of the Metalloprotease System Mediating Oncogenic NOTCH1 Activation in T-ALL.. Blood, 2009, 114, 988-988.	0.6	0
102	Notch Signaling Is Required for Mast Cell Development in the Zebrafish.. Blood, 2009, 114, 3588-3588.	0.6	4
103	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	0.6	3
104	Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol. Blood, 2008, 112, 2548-2548.	0.6	0
105	Challenges and Opportunities for Effective NOTCH1 Targeting in T-ALL.. Blood, 2008, 112, sci-30-sci-30.	0.6	0
106	Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. Blood, 2008, 112, 200-200.	0.6	0
107	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. Journal of Experimental Medicine, 2007, 204, 1825-1835.	4.2	427
108	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. Blood, 2007, 110, 151-151.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2007, 110, 5-5.	0.6	2
110	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
111	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18261-18266.	3.3	745
112	Identification of Oncogenic Pathways of T-Acute Lymphoblastic Leukemia (T-ALL) through Gene Expression Profiling of Mouse Tumor Models.. Blood, 2006, 108, 2234-2234.	0.6	0
113	Transcriptional Regulatory Networks Downstream of NOTCH1 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 740-740.	0.6	15
114	Activating Notch1 Mutations Are an Early Event in T-Cell Malignancy of Ikaros Point Mutant Mice.. Blood, 2005, 106, 2616-2616.	0.6	0
115	A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 89-89.	0.6	1
116	Microarray Analyses in a Case-Control Cohort of T-ALL Samples Identifies Gene Signature of Potential Prognostic Significance.. Blood, 2005, 106, 1448-1448.	0.6	0
117	DNA Microarrays in the Diagnosis and Management of Acute Lymphoblastic Leukemia. International Journal of Hematology, 2004, 80, 395-400.	0.7	21
118	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science, 2004, 306, 269-271.	6.0	2,494
119	Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood, 2004, 103, 1909-1911.	0.6	117
120	Genome-Wide Transcriptional Regulatory Networks Downstream of TAL1/SCL in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 416-416.	0.6	7
121	Identification of TAL1/SCL Target Genes through siRNA and Microarray Expression Analysis.. Blood, 2004, 104, 4294-4294.	0.6	8
122	Gene expression profiling: will it complement or replace immunophenotyping?. Best Practice and Research in Clinical Haematology, 2003, 16, 645-652.	0.7	5
123	Gene expression profiling in T-cell acute lymphoblastic leukemia. Seminars in Hematology, 2003, 40, 274-280.	1.8	124
124	Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood, 2003, 102, 262-268.	0.6	298